Kornimate/medical-research-clean huggingface dataset:
neutrophil extracellular traps mediate antiphospholipid antibody-induced pregnancy loss

Conditions: Neutrophil Extracellular Traps; Antiphospholipid Antibody-induced Pregnancy Loss

Summary: 1. establish a multi-platform detection system for neutrophil extracellular traps in blood and tissues, and evaluate the detection performance; 2. comparing the expression levels of neutrophil extracellular traps in peripheral blood and decidua of patients with antiphospholipid antibody-induced pregnancy loss and normal control group; 3. comparing the expression levels of neutrophil extracellular traps in peripheral blood and decidua of mice with antiphospholipid antibody-induced pregnancy loss and normal control group; 4. after treatment of antiphospholipid antibody-induced mouse abortion model with metformin,the effect of metformin on embryo loss rate and viable embryo body weight was observed.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of recurrent spontaneous abortion * clinical diagnosis of antiphospholipid syndrome exclusion criteria: * other autoimmune diseases * hematopoietic system diseases * cardiovascular system diseases * gastrointestinal system diseases * urinary system diseases * nervous system or mental diseases * have taken other drugs recently
endoscopic severity image recognition to advance research and training in inflammatory bowel disease (everest - ibd)

Conditions: Inflammatory Bowel Disease 1

Summary: to develop and train a convolutional neural network to detect and characterize disease severity of inflammatory bowel disease during endoscopy

to develop and train a convolutional neural network to detect and characterize disease severity in inflammatory bowel disease during endoscopy. this initiative will inevitably establish a high-quality large image database. our secondary study aims are therefore to use the images we collect to advance the field of deep learning and computer aided diagnosis in inflammatory bowel disease by establishing an image database. this will involve developing a framework combining deep learning and computer vision algorithms. the ultimate aim is to use the image database to produce high impact research outcomes and training resources leading to an improvement in the quality of endoscopy performed, reduce inter-observer variability in disease assessment and a reduction in missed bowel cancer rates and associated mortality.

Eligibility criteria:
inclusion criteria: * • any adult patient aged 16 years or older who has consented to undergo endoscopic investigation where images are captured as part of routine clinical care. exclusion criteria: * • any patient under the age of 16 * patients who are unable to give informed consent to undergo endoscopic investigation or those who do not wish their pseudo-anonymised images to be used
adult iatrogenic withdrawal study in the icu (alert-icu)

Conditions: Withdrawal Syndrome; Iatrogenic Disease

Summary: withdrawal from opioids and sedatives administered for medical purposes (i.e. iatrogenic withdrawal) often goes unrecognized in the critically ill, but its prevalence is high. reports describing what is being implemented at the bedside to prevent iatrogenic withdrawal are lacking, and how patients are monitored and assessed for withdrawal has not been adequately studied. therefore, the investigators overall objective is to determine the current analgesia and sedation weaning practices in adult icus. in order to accomplish this objective the investigators plan to conduct a prospective, observational, point prevalence trial. data from this project will help support future investigation of iatrogenic withdrawal.

the design for this study will be an international, prospective, observational, point prevalence trial. the investigators plan to recruit multiple sites to participate in the study through the use of professional organization list serves as well as direct outreach to colleagues and associates of members of the investigator team. data collection will be performed by site investigators on one single day for all patients currently in the icu who meet inclusion criteria on the data collection day. site investigators will have an approximately three-month time frame in which to choose a data collection date. all data collection will be performed using redcap, a secure web-based data collection tool that meets the hipaa (health insurance portability and accountability act of 1996) requirements for protection of patient health information. utilization of this system will allow real-time input of data from the patient's bedside by site investigators. data collected will include various site and patient demographic data. the investigators will also collect opioid and sedative doses, durations of therapy, weaning of doses, and withdrawal assessment results.

Eligibility criteria:
inclusion criteria: * all patients 18 years and older admitted to an adult intensive care unit on the day of data collection who have received parenteral analgesics or sedatives in the previous 24 hours. exclusion criteria: * patients who have not received parenteral analgesics or sedatives in the previous 24 hours.

Keywords: opioid withdrawal benzodiazepine withdrawal narcotic withdrawal critically ill
meningioma detection using non contrast mri techniques

Conditions: Meningioma

Summary: meningioma, an extra-axial brain tumor developed at the expense of meninges, accounts for 35% of central nervous system tumors, and its incidence is estimated at 3% in large autopsy series. the current gold standard for screening and monitoring cerebral meningiomas is mri with injection of gadoline-contrast product. however, the use of some of these products is problematic, due to gadolinium deposits observed in patients who have had several injections during their lifetime, especially in patients followed for multiple sclerosis. recently, the french national agency for the safety of medicines and health products (ansm) issued recommendations concerning the screening of meningiomas in patients at risk, particularly in people treated with cyproterone acetate. it is a synthetic progestogen steroid with anti-androgenic properties. it is used to treat hyperandrogenic syndromes in women or in the palliative treatment of prostate cancer in men. its long-term use seems to be associated with a significant over-risk of developing meningiomas, brain tumours affecting meninges. this increased risk is multiplied by 7 in women exposed to high doses of cyproterone acetate, and by 20 over a cumulative dose of 60 grams, or about 5 years of treatment at 50 mg/day or 10 years at 25 mg/day. the ansm recommends that a cerebral mri be performed at the beginning of treatment for all patients, as well as a control mri renewed at 5 years and then every 2 years if the mri at 5 years is normal. these recommendations will lead to a large number of mris involving an injection of contrast agent in this population, with potential immediate or delayed serious adverse effects. new techniques, such as arterial spin labelling (asl), or black blood sequences optimized for contrast detection, have been developed. these could detect meningeal anomalies and more particularly meningiomas without contrast injection, or with a significantly lower dose of contrast agent. these techniques have not been specifically studied for screening or monitoring meningeal lesions, but it seems relevant and important to be able to validate protocols that reduce gadolinium doses given the high number of screening and follow-up mris in the general population. patients presenting for brain mri for meningioma screening or follow-up will have the usual mri sequences for their management, and the fabir sequences without injection, added for research. these new sequences will add approximately 8 minutes of additional examination time.


Eligibility criteria:
inclusion criteria: * patient over 18 years of age * patient performing mri as part of a screening or follow-up of known meningioma * express consent to participate in the study exclusion criteria: * contraindication for mri (electrical device, metallic foreign body, claustrophobia) * known hypersensitivity to the contrast medium (gadolinium) * known renal failure: glomerular filtration rate \<30ml/min * patient benefiting from a legal protection measure * pregnant or breastfeeding woman
efficacy and safety of macugen in patients with neovascular amd in routine clinical practice.

Conditions: Neovascular Age-related Macular Degeneration

Summary: efficacy and safety of macugen in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.

eligible patients in routine clinical practice

Eligibility criteria:
inclusion criteria: adults with neovascular age-related macula degeneration exclusion criteria: according to smpc

Keywords: efficacy and safety of macugen in routine clinical practice
effectiveness of warm packs, perineal massage and hands off during labour in the perineal outcomes.

Conditions: Perineal Tear

Summary: this study evaluates the effectiveness of warm packs, perineal massage and hands off, during labour, in the perineal outcomes. the perineal outcomes are perineal tears, grade of perineal tears, need of suture, perineal edema, perineal pain, use of drugs for perineal pain, and satisfaction with the technique used.

this study is a randomised controled trial.

Eligibility criteria:
inclusion criteria: * parturient in active phase of labour * single fetus at term (37-42 weeks) * bent cephalic fetal presentation * parity less than four children exclusion criteria: * use any perineal preparation techniques during pregnancy * clinical indication for caesarean section

Keywords: perineal tear pain pelvic floor labour
study of circulating tumoral dna in metastatic choroidal melanoma

Conditions: Choroidal Melanoma, Diffuse

Summary: circulating tumor dna detection and quantification in patients with metastatic choroidal melanoma.

technique development: in first step, the different available techniques will be evaluated for specificity and sensibility using serial dilutions of cell lines with or without gnaq mutation. validation: the tumor dna detection rate will be estimated from metastatic uveal patient's blood. the investigators will study 40 patients to obtain at least 15 patients bearing a gnaq mutation in the primitive tumor or in metastasis. with those 15 patients, the investigators will determinate the most sensitive technique and the best cost/efficiency ratio.

Eligibility criteria:
inclusion criteria: * age \> or = 18 years. * patient with a metastatic choroidal melanoma. * patient with tumor or metastasis available for gnaq (guanine nucleotide blinding protein) status characterization. * patient able to stand a blood collection. * signed written informed consent approved by competent authority and ethic committee. exclusion criteria: * patient without social protection/insurance. * current pregnancy and lactation. * all social, medical, psychological, situations making the study impossible. * person deprived of liberty.

Keywords: circulating tumor dna choroidal melanoma
the effects of video-based and practical newborn bathing education provided to primiparous pregnant women during the third trimester on knowledge, anxiety, and bonding during the first bath: a randomized controlled trial

Conditions: Newborn Bathing; Primiparous Pregnant Women; Anxiety; Bonding; Knowledge

Summary: this study will be conducted in a randomized controlled experimental research design with pretest, posttest control group.

this study will be conducted in a randomized controlled experimental research design with pretest, posttest control group.

Eligibility criteria:
inclusion criteria: * can speak and understand turkish, * 18 years of age or older, * literate, * primiparous, * in the third trimester of pregnancy, * a singleton pregnancy, * no psychiatric illness, * who have not received any training on newborn bathing before, * her baby was not diagnosed with a fetal anomaly, * with a smartphone and internet, * residing in the province of kahramanmaras and * who agreed to participate in the research exclusion criteria: * preterm labor (\&lt;37 weeks gestation), * stillbirth, * the baby needs intensive care or is hospitalized, * the baby has a low birth weight (\&lt;2500 grams), * the one whose baby\&#39;s first bath was given by someone else, * a newborn bathing program was organized at the pregnancy school. * wishing to leave at any stage of the study.

Keywords: newborn bathing primipar education
biomarkers in predicting response in patients with graft-versus-host disease undergoing extracorporeal photophoresis

Conditions: Graft Versus Host Disease (GVHD)

Summary: this clinical trial studies biomarkers in predicting response in patients with graft-versus-host disease (gvhd) undergoing extracorporeal photopheresis (ecp). ecp treats the patient's blood with ultraviolet light outside the body and kills the white blood cells before returning blood back into the patient's body. studying samples of blood from patients with gvhd may help doctors identify and learn more about biomarkers related to gvhd.

primary objective: i. to show that extracorporeal photopheresis (ecp)increases skin and gut homing t regulatory (t-reg) cells in patients with gvhd clinically responding to ecp. secondary objectives: i. response rates of gvhd with extracorporeal photopheresis(ecp)as measured by nih response criteria ii. incidence of t-reg cell frequency(%)with various nih subtypes of chronic graft-versus-host disease (gvhd) iii. incidence of t-reg homing subsets(%)with various nih subtypes of chronic graft-versus-host disease (gvhd) outline: patients undergo ecp twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks. after completion of study treatment, patients are followed up at 2, 4, and 6 months.

Eligibility criteria:
inclusion criteria: * patients with any nih subtype of chronic gvhd that is being treated with ecp * karnofsky performance scale (kps) \> 60% at time of study enrollment * life expectancy \> 3 months * steroid dose not greater than 2 mg/kg prednisone equivalent at time of study enrollment * if patient has steroid refractory gvhd (defined as worsening of gvhd after 3 days of 2 mg/kg prednisone equivalent or no improvement after 7 days of 2 mg/kg prednisone equivalent), time interval from start of steroids to initiation of ecp should not be \> 14 days * no use of an investigational agent within 2 weeks of starting ecp * no uncontrolled bacterial, fungal or viral disease (therapy for cytomegalovirus \[cmv\] viremia is permitted) * no evidence of relapse or progression of underlying disease (molecular evidence of relapse/progression or mixed chimerism is permitted) * women of childbearing potential (wocbp) should be willing to use 2 forms of contraception; male patients should be willing to use contraception * voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care exclusion criteria: * female patients who are breastfeeding or pregnant * patients known to be human immunodeficiency virus (hiv) positive * bronchiolitis obliterans as the sole indication of ecp * serious medical or psychiatric illness likely to interfere with participation in this clinical study * mechanical ventilation, renal replacement therapy, admitted in intensive care until at time of enrollment * stage 4 gastrointestinal gvhd as per seattle-glucksberg criteria
multi-center phase ii study assessing the safety and efficacy of de-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study is to investigate the safety and efficacy of five concentrations of de-117 ophthalmic solution.

this is a 90-day randomized, observer-masked, active-controlled, parallel-group, multi-center, study assessing the safety and efficacy of five concentrations of de-117 ophthalmic solution when compared to latanoprost (0.005% latanoprost) in subjects with primary open-angle glaucoma or ocular hypertension.

Eligibility criteria:
inclusion criteria: * current diagnosis of primary open-angle glaucoma or ocular hypertension in both eyes * qualifying intraocular pressure in at least one eye at baseline * qualifying corrected etdrs visual acuity in each eye * qualifying central cornea thickness in each eye exclusion criteria: * closed/barely open anterior chamber angle or a history of acute angle closure in either eye * diagnosis of primary open-angle glaucoma or ocular hypertension due to etiology known to be non-responsive to conventional drug therapy * evidence of advanced glaucoma, visual field defect or progressive visual field loss that that do not meet the study criteria * history of ocular surgery specifically intended to lower iop * history of any ocular or systemic abnormality or condition that may put the subject at significant risk, may confound study results, or may interfere significantly with the subject's participation in the study * intended or current use of any ocular medications other than study medications during the study * use of contact lenses within one week prior to baseline (day 1) until end of treatment * known allergy or sensitivity to any components of the study medications * use of steroids (systemic) within 30 days prior to visit 1 (screening) * anticipate the need to initiate or modify an existing chronic therapy that could substantially affect iop or the study outcomes during the study period * females who are pregnant, nursing or planning a pregnancy

Keywords: santen eye glaucoma ocular hypertension
targeted act compared to supportive therapy for depression rct

Conditions: Acceptance and Commitment Therapy; Supportive Therapy

Summary: acceptance and commitment therapy (act) has demonstrated efficacy in reducing depressive symptoms, primarily compared to no treatment or minimal treatment controls. this study compared the efficacy of act targeting cognitive defusion (cd, 3 sessions) and values-based activity scheduling (vbas, 3 sessions) to supportive therapy (st). both treatments offered six sessions, a rationale for the approach, related techniques, and homework assignments. a parallel group randomized controlled efficacy trial design was used. participants were stratified by gender identification and depression severity and then randomly allocated, according to a predetermined sequence, 2:1 to act or st. dependent measures were collected during acute treatment (pre, mid, and post-treatment) and follow-up at one-month.


Eligibility criteria:
inclusion criteria: * 18 years or older * scored one sd below the mean on the rses and bsi * proficiency in english * if taking medication for psychiatric reasons, stable medication use for at least eight weeks prior to enrollment and agreement to no changes in dosing during study participation. exclusion criteria: * receiving other forms of psychological treatment * meeting pdsq interview criteria for psychosis, panic disorder, substance use, or endorsement of significant suicidal ideation
predictable mr index for nonalcoholic steatohepatitis (nash)

Conditions: Nonalcoholic Steatohepatitis

Summary: 1. to evaluate feasibility of using multiparametric magnetic resonance(mr) imaging to predict nonalcoholic steatohepatitis(nash) 2. to develop non-invasive diagnosis tool using multiparametric magnetic resonance(mr) imaging for nonalcoholic steatohepatitis(nash)

nonalcoholic steatohepatitis(nash) is a severe form of nonalcoholic fatty liver disease(nafld). the causes are known to be associated with metabolic diseases such as obesity, insulin resistance type 2 diabetes, and hypercholesterolemia. histologically, it is characterized by steatosis, hepatocellular injury, and inflammation and fibrosis of the liver parenchyma. nonalcoholic steatohepatitis (nash) may progress to cirrhosis and hepatocellular carcinoma(hcc) may develop even in patients without viral hepatitis, therefore there have been much interest and many researches in causation and diagnosis for nonalcoholic steatohepatitis(nash). liver biopsy remains the gold standard for the diagnosis of nonalcoholic fatty liver disease(nafld) and is the only reliable method for differentiating nonalcoholic steatohepatitis(nash) from simple steatosis. however, liver biopsy has several drawbacks, including invasiveness, potential complications such as excessive bleeding and death, sampling error, and inter- and intra-observer variability. magnetic resonance(mr) imaging has been used as a multiparametric imaging tool with which to evaluate steatosis by chemical shift imaging andm magnetic resonance(mr) spectroscopy, and fibrosis by magnetic resonance(mr) elastography and t1 mapping. to the best of our knowledge, there is no accurate imaging diagnostic tool for nonalcoholic steatohepatitis(nash), therefore the investigators aimed to develop non-invasive imaging diagnostic model using multiparametric magnetic resonance imager(mri).

Eligibility criteria:
inclusion criteria: 1. patients \>19 years age 2. patients who had elevated aspartate transaminase(ast)/alanine transaminase(alt) and fatty liver on abdominal ultrasonography 3. patients who are clinically suspected to have nonalcoholic steatohepatitis(nash) * clinically suspected nonalcoholic steatohepatitis(nash): \>40 years age, metabolic syndrome, fibrosis on transient elastography(te, fibroscan), or elevated fibrosis-4(fib-4), aspartate aminotransferase-to-platelet ratio index(apri), nonalcoholic fatty liver disease fibrosis score(nfs) on blood tests 4. patients who underwent (\<6 months) or will undergo us-guided liver biopsy exclusion criteria: 1. chronic liver disease other than nonalcoholic fatty liver disease(nafld) (chronic hepatitis b or c, autoimmune hepatitis, primary biliary sclerosis) 2. alcohol abuse (men, \>140g/week; women, \>70g/week) 3. fatty liver due to medication 4. contraindication to magnetic resonance imager(mri) 5. hepatocellular carcinoma 6. pregnancy

Keywords: magnetic resonance imager(mri) nonalcoholic fatty liver disease(nafld) imaging diagnostic